| Title: | Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank |
| Journal: | Frontiers in Pharmacology |
| Published: | 10 Nov 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/36438798/ |
| DOI: | https://doi.org/10.3389/fphar.2022.949699 |
| URL: | https://www.frontiersin.org/articles/10.3389/fphar.2022.949699/pdf |
| Citations: | 12 (12 in last 2 years) as of 8 Aug 2024 |
Publication 10678
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background: Proton pump inhibitors (PPIs) are widely used and have been linked to kidney diseases. However, the role of PPI use in the development of chronic kidney disease (CKD) remains unclear. We undertook this study to examine the association between PPI use and the subsequent risk of CKD. Methods: This is a prospective analysis of 462,421 participants free of cancer diagnosis or chronic kidney disease from the United Kingdom Biobank. Self-reported PPI use was recorded using an electronic questionnaire and confirmed by a trained staff. Incident CKD was identified based on the medical history. Overlap propensity score weighting with the Cox model was used to calculate the effect of PPI use on CKD risk. The number needed to harm (NNH) was calculated at 5 and 10 years of follow-up. Results: We documented 7,031 cases of CKD over a median follow-up of 8.1 years. Overlap propensity score weighting analysis showed that regular PPI users had a 37% higher risk of CKD incident than non-users (HR 1.37, 95% CI 1.28-1.47). The association persisted across subgroup analyses, different types of PPIs, and several sensitivity analyses. Quantitative bias analysis indicated that the result was robust to unmeasured confounding (E-value 2.08, lower 95% CI 1.88). The NNH was 147.9 and 78.6 for 5 and 10 years of follow-up, respectively. A head-to-head comparison showed that PPI users had a 19% higher risk of CKD than H2RA users (HR 1.19, 95% CI 1.02-1.39). Conclusion: The regular use of PPI is associated with a higher risk of CKD. Healthcare providers should carefully weigh up the potential benefits against the risk in prescribing PPIs, particularly for patients requiring long-term treatment.</p>
6 Authors
- Xing-Yu Zhang
- Qiang-Sheng He
- Zhong Jing
- Juan-Xia He
- Jin-Qiu Yuan
- Xiao-Yu Dai
1 Application
| Application ID | Title |
|---|---|
| 51671 | Metabolism syndrome and risk of cancer |
Enabling scientific discoveries that improve human health